Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Study acronym: MagnetisMM15
StatusRecruiting
PhasePhase 4
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 4 of 33 sitesv34
  2. Trial sites expanded: 28 → 33 locationsv33
  3. Site details revised at 3 of 28 sitesv32
  4. Trial sites expanded: 15 → 28 locationsv31
  5. Trial sites reduced: 28 → 15 locationsv30
Show 28 earlier versionsHide 28 earlier versions
  1. Study sites: 29 to 28v29
  2. Study sites: 25 to 29v28
  3. Study sites: 26 to 25v27
  4. Study sites: 25 to 26v26
  5. Study sites: 24 to 25v25
  6. Study sites: 19 to 24v24
  7. Site details revised at 1 of 19 sitesv23
  8. 3 versions Re-verified since Sep 19, 2025, no change to tracked fieldsv20-v22
  9. Study sites: 18 to 19v19
  10. Study sites: 11 to 18v18
  11. Study sites: 7 to 11v17
  12. Study sites: 6 to 7v16
  13. Site details revised at 1 of 6 sitesv15
  14. Study sites: 5 to 6v14
  15. Study sites: 4 to 5v13
  16. Study sites: 3 to 4v12
  17. 2 versions Re-verified since Feb 18, 2025, no change to tracked fieldsv10-v11
  18. Primary and study completion dates: Feb 22, 2031 to Feb 22, 2032
    • Enrollment target: 72 to 80
    • Study sites: 13 to 3
    v9
  19. Re-verified, no change to tracked fieldsv8
  20. Study sites: 5 to 13v7
  21. Study sites: 4 to 5v6
  22. Study sites: 3 to 4v5
  23. Site details revised at 1 of 3 sitesv4
  24. Study sites: 2 to 3
    • Start date changed from estimate of Oct 2, 2023 to Oct 3, 2023
    v3
  25. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date: Sep 26, 2023 to Oct 2, 2023
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
441 trials monitored
See 31 trials at risk
Multiple Myeloma
1,273 trials monitored
See 83 trials at risk
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Trial Details
NCT Number NCT06057402
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov